Otto Kauko

The paper introduces DASH-PISA, a method for automated thermal proteome profiling that enables high-throughput compound screening by improving efficiency and reducing costs.

The paper identifies a co-dependency between CDK12 and the BAF chromatin-remodeling complex in TNBC, showing that their co-inhibition synergistically reduces cancer cell viability.

This study shows that queuosine modification in Shewanella glacialimarina is essential for cold-active growth, as its deficiency leads to cold sensitivity and metabolic changes.

This study identifies keratin 7 (K7) protein in stool as a noninvasive biomarker for active pediatric-onset inflammatory bowel disease, showing high sensitivity and specificity.

This study shows that DTP cells in EGFR-mutant lung cancer drive immunosuppression through YAP/TEAD activity, and co-targeting YAP/TEAD improves EGFR TKI therapy efficacy.

The paper develops an ML-powered drug discovery pipeline to design selective CK2 inhibitors with favorable off-target profiles, achieving a 90% hit-rate.

This study identifies BX-912 as a therapeutic agent for ovarian serous carcinoma, revealing HES1 as a target and showing synergistic effects with olaparib.

This paper identifies S166 phosphorylation on LSD1 as a regulatory switch that controls gene activation, chromatin remodeling, and tumor microenvironment in non-hormonal cancer cells.

This study uses a novel competitive genome editing assay to identify MYC oncogene transcriptional targets by analyzing the effects of E-box mutations on cellular fitness.

The paper identifies a PP2A-Integrator complex that opposes CDK9 activity to regulate transcription and shows its therapeutic synergy in leukemia.

The paper presents a systemic analysis of PP2A-regulated phosphosignaling and drug responses, revealing rules for phosphoregulation and cancer therapy classification.